The thyroid hormone receptor beta (TR-β) signaling controls pathogenic Th17 cells in autoimmune disease
International Immunology · 2025
DOI: 10.1093/intimm/dxaf045 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, 2025. Verfasst von Yoshimitsu Doi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-850…. Hauptthemen laut MEDLINE: Th17 Cells, Encephalomyelitis, Autoimmune, Experimental, Thyroid Hormone Receptors beta. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Ministry of Health, Labor and Welfare of Japan.
Abstract (Originalsprache)
The role of the thyroid hormone receptor beta (TR-β) in the immune system remains poorly understood; although its effect on TGF-β signaling has been reported in nonimmune systems. Here, we report that Thrb is highly expressed in pathogenic CD4+ T cells that infiltrate the central nervous system during experimental autoimmune encephalomyelitis (EAE), and Thrb is exclusively expressed in IL-17-producing CD4+ T cells (Th17 cells) that develop both in vitro or in vivo. Sobetirome, a selective TR-β agonist, promoted pathogenic Th17 differentiation and IL-17 production in the presence of exogenous IL-1β. Conversely, small interfering RNA (siRNA)-mediated silencing of TR-β reduced IL-17 production, further supporting a T cell-intrinsic role of TR-β. Because C75, an inhibitor of de novo lipogenesis, blocked Th17 cell differentiation by sobetirome, the influence of TR-β signaling on Th17 cell induction is likely to act via a de novo lipogenesis-dependent mechanism. Furthermore, blocking TR-βexpression by siRNA changed the balance of IL-10/IL-17 production in cultured splenocytes, favoring an IL-10 phenotype. In contrast, IL-10 production by T cells was attenuated by activating TR-β signaling with sobetirome. Finally, the manipulation of TR-β signaling altered the severity of autoimmune disease: blocking TR-β reduced passive EAE and enhancing TR-β increased active EAE. These effects were accompanied by corresponding changes in the IL-10/IL-17 balance in encephalitogenic CD4+ T cells. In summary, our results demonstrate that TR-β signaling controls pathogenic Th cell function and autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan.
- Department of Internal Medicine, Seikeikai Hospital, 1-1-1 Minamiyasui, Sakai, Osaka 590-0064, Japan.
- Department of Neurology, Kyoto University Graduate School of Medicine, Yoshida-konoe-cho, Sakyo, Kyoto 606-8501, Japan.
ORCID-Profile: Ben J E Raveney, Kimitoshi Kimura
Förderung
- Ministry of Health, Labor and Welfare of Japan
Zitieren
APA
Doi, Y., Raveney, B. J. E., Kimura, A., Mallahalli, M. S., Kimura, K., Sato, W., Oki, S., & Yamamura, T. (2025). The thyroid hormone receptor beta (TR-β) signaling controls pathogenic Th17 cells in autoimmune disease. International Immunology. https://doi.org/10.1093/intimm/dxaf045
Vancouver
Doi Y, Raveney BJE, Kimura A, Mallahalli MS, Kimura K, Sato W, et al. The thyroid hormone receptor beta (TR-β) signaling controls pathogenic Th17 cells in autoimmune disease. International Immunology. 2025. doi:10.1093/intimm/dxaf045
BibTeX
@article{Doi2025,
author = {Doi, Yoshimitsu and Raveney, Ben J E and Kimura, Atsuko and Mallahalli, Manu S and Kimura, Kimitoshi and Sato, Wakiro and Oki, Shinji and Yamamura, Takashi},
title = {The thyroid hormone receptor beta (TR-β) signaling controls pathogenic Th17 cells in autoimmune disease},
journal = {International Immunology},
year = {2025},
doi = {10.1093/intimm/dxaf045}
}
EUVIMED